

FOR RELEASE, June 19, 2008

Trinity Biotech to Close NASDAQ Stock Market in Honor of National HIV Testing Day

DUBLIN, Ireland (June 19th, 2008)...Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it will preside over the closing of The NASDAQ Stock Market in recognition of U.S. National HIV Testing Day.

June 27, 2008, marks the fourteenth annual U.S. National HIV Testing Day, an annual campaign sponsored by the National Association of People with AIDS to encourage at-risk individuals to receive voluntary HIV counseling and testing. According to the Centers for Disease Control and Prevention, an estimated 180,000 to 280,000 Americans are HIV-positive but are unaware of their status. HIV counseling and testing enables people with HIV to take steps to protect their own health and that of their partners, and helps people who test negative to get the information they need to stay uninfected.

Dr. Monica Sweeney, Assistant Commissioner of the New York City Health Department's Bureau of HIV/AIDS Prevention and Control, was quoted as saying, "National HIV Testing Day reminds us of the importance of knowing your HIV status. Let's work to make testing a routine part of medical care, which is the best way to save lives."

Brendan Farrell, Chief Executive Officer of Trinity Biotech, commented "We are honored to assist so many dedicated health jurisdictions to help stem the spread of the HIV virus, and proud to be able to close The NASDAQ Stock Market on such an important date. In order to help stop the spread of HIV/AIDS and provide treatment to those in need, it is critical that individuals who may be infected learn their HIV status. We believe that Trinity's Uni-Gold™ Recombigen® HIV test, with its 10 minute result, earlier detection capability, and 100% sensitivity, will increase the number of people who learn their HIV results, and we will continue to work aggressively in partnership with local, state and national agencies to help make this happen."

Trinity's Uni-Gold™ Recombigen® HIV test was launched in the USA in 2004. Since then sales of the product have grown rapidly through increased penetration of both the public health and hospital based markets. In a recent study, Uni-Gold™ demonstrated far superior performance to all currently available FDA approved CLIA-waived rapid tests currently available

on the market. Furthermore, this highly accurate test, with 100% sensitivity, even outperformed an FDA-approved, "moderately complex" rapid test. For further information on rapid HIV testing and Uni-Gold™ Recombigen® HIV, please see: <http://www.unigoldhiv.com/> or call 800.325.3424.

On June 27, 2008, NASDAQ will host New York City Department of Health Assistant Commissioner Dr. Monica Sweeney, M.D. together with Brendan Farrell, Trinity's Chief Executive Officer, and David Oxley, Trinity's Executive Vice President, to preside over the NASDAQ Market Close ceremony, beginning at 3:50 p.m. ET. Following the event, the Market Close ceremony will be available for viewing online at http://www.nasdaq.com/reference/marketsite_about.stm.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

| | | |
|-----------------|--|---|
| Contact: | Trinity Biotech plc Ms. Niamh Long Investor Relations Officer (353)-1-2769800 niamh.long@trinitybiotech.com | Joe Diaz, Joe Dorame, Robert Blum Lytham Partners, LLC (602) 889-9700 |
|-----------------|--|---|

END OF RELEASE